|2023-9-11||CITIC CLSA Investors’ Forum||Hongkong|
|2023-11-7||CITI China Investor Conference||Shenzhen|
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicating to providing competitive products and services to fulfill the unmet clinical needs.
CMS focuses on developing first- or best-in-class innovative products and has deployed 30 differentiated pipeline products with relatively high level of innovation and great market potential. CMS deeply engages in specialty therapeutic fields. It has developed proven commercialization capabilities, extensive network and expert resources, and won leading academic and market positions for its major marketed products. With deeply rooted in the specialty areas while expanding its business boundaries, it continued to strengthen the competitiveness of its cardio-cerebrovascular/ gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business to enhance the scale and efficiency of operation; Meanwhile, it entered into the Southeast Asian market to create new driving force, further escorting the sustainable and healthy development of the Group.